Edward B. Garon, MD, MS | Authors


Clinical Implications of Recent Advancements in Immunotherapy for NSCLC

February 03, 2023

In the third installment of this series, Edward B. Garon, MD, MS, gives a historical overview of first-line immunotherapy options for non–small cell lung cancer, discusses the recent FDA approval of durvalumab/tremelimumab in combination with platinum-based chemotherapy in the same setting, and assesses treatment and research goals in the field.

First-Line Treatment of mNSCLC with Combination Immunotherapy plus Chemotherapy and Key Data Updates from POSEIDON

December 20, 2022

In the second installment of this series, Edward B. Garon, MD, MS, explains the rationale for using combination IO therapies alongside chemotherapy for first-line treatment of metastatic non-small cell lung cancer (NSCLC), discusses key data from the POSEIDON trial presented at recent meetings, and elaborates on how these regimens may change his clinical practice.